Chemical Structure
PF-2545920 [898562-94-2]
AG-CR1-3636
Overview
- SupplierAdipoGen Life Sciences
- Product NamePF-2545920
- Delivery Days Customer10
- CAS Number898562-94-2
- CertificationResearch Use Only
- Estimated Purity>98%
- Hazard InformationWarning
- Molecular FormulaC25H20N4O
- Molecular Weight392.5
- Scientific DescriptionChemical. CAS: 898562-94-2. Formula: C25H20N4O. MW: 392.5. Potent and selective phosphodiesterase 10A (PDE10A) inhibitor (IC50=1.26nM) in vitro and in vivo. PDE10A is a cGMP and cAMP degrading PDE isozyme with neurological importance and was shown to be implicated in the regulation of energy homeostasis. Inhibition of PDE10A leads to interference of the breakdown of the secondary messenger cAMP and cGMP. Anti-psychotic agent. Useful for the treatment of schizophrenia. Anticancer agent. Inhibits colon tumor cell growth for which high levels of PDE10A have been reported. Antiobesity and antidiabetic agent. Induces browning in white adipose tissue (WAT). - Potent and selective phosphodiesterase 10A (PDE10A) inhibitor (IC50=1.26nM) in vitro and in vivo. PDE10A is a cGMP and cAMP degrading PDE isozyme with neurological importance and was shown to be implicated in the regulation of energy homeostasis. Inhibition of PDE10A leads to interference of the breakdown of the secondary messenger cAMP and cGMP. Anti-psychotic agent. Useful for the treatment of schizophrenia. Anticancer agent. Inhibits colon tumor cell growth for which high levels of PDE10A have been reported. Antiobesity and antidiabetic agent. Induces browning in white adipose tissue (WAT).
- SMILESCN(C=C1C2=CC=NC=C2)N=C1C(C=C3)=CC=C3OCC4=NC5=CC=CC=C5C=C4
- Storage Instruction-20°C,2°C to 8°C
- UNSPSC12352200
References
- Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia: P.R. Verhoest, et al.; J. Med. Chem. 52, 5188 (2009)
- Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia: S.M. Grauer, et al.; J. Pharmacol. Exp. Ther. 331, 574 (2009)
- Effects of phosphodiesterase 10 inhibition on striatal cyclic AMP and peripheral physiology in rats: A. Torremans, et al.; Acta Neurobiol. Exp. 70, 13 (2010)
- Phosphodiesterase 10A inhibitor, MP-10 (PF-2545920), produces greater induction of c-Fos in dopamine D2 neurons than in D1 neurons in the neostriatum: J.M. Wilson, et al.; Neuropharmacol. 99, 379 (2015)
- beta-catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG: K. Lee, et al.; Oncotarget 7, 5353 (2016)
- A novel thermoregulatory role for PDE10A in mouse and human adipocytes: M.K. Hankir, et al.; EMBO Mol. Med. 8, 796 (2016)